Down syndrome is characterized by mild to moderate cognitive impairments that are caused by trisomy of chromosome 21. Several anatomical, behavioral, electrophysiological, and developmental abnormalities have been associated with Down syndrome. In this review, the current knowledge about the neurobiology of this disease and future perspectives of pharmacological treatments for this condition will be discussed.